A revolutionary device developed by a team of Cambridge scientists is transforming the diagnosis of HIV in sub-Saharan Africa. The machine — known as SAMBA, or simple amplification-based assay — can help determine whether a person is infected with the virus within two hours of them giving a tiny blood sample. Virus carriers can then be offered immediate treatment and advice.
More than 20 million people in sub-Saharan Africa are thought to be carrying HIV, the virus that causes AIDS. The chaotic conditions in some parts of the region — with transport, health services and electricity supply often poor or nonexistent — have made it extraordinarily difficult for doctors to keep track of infected people.
The new analyser — the size of a small coffee machine — which was developed by a team led by Helen Lee, a Cambridge University professor of blood scientist, needs no laboratory or trained staff. It can be carried on a motorcycle — often the only method of transport in remote regions — and its reagents can withstand high temperatures and humidity.
“Basically, they will still work even if the heat goes above 50oC,” Lee said.
In recognition of her team’s achievement in developing SAMBA, Lee has been named a finalist in this year’s European inventor awards. Winners are to be announced in Lisbon this week.
“The crucial point about our device is that it provides you with a simple signal,” Lee told the Observer. “If two lights are produced, that shows a person has been infected with HIV. If only one light shines, they are not infected. We can show it to a patient and explain to them exactly what the lights mean and what is going on. That is a very powerful way to convince someone of their condition.”
Working in close collaboration with charity Medecins Sans Frontieres, Lee and her colleagues have tested SAMBA on 40,000 men and women in Malawi and Uganda since the first prototype was developed in 2011 and found it works extremely efficiently. Each test costs about £12 (US$17.6) to administer.
“Now we are going to expand testing for HIV to pregnant women, mothers and newborn children, starting in Kenya,” Lee said. “That has all sorts of potential. For example, if we find a woman is infected, but not her newborn child, we can give advice her about how to prevent the baby picking up the virus during his or her infancy.”
The ability to make quick diagnoses is considered to be of crucial importance in controlling HIV in Africa. Until now, people have had to travel to health centers to provide a blood sample and then return weeks later for the results of their test. Up to 70 percent of patients will fail to return and are designated “lost to follow-up.” Lee’s tests should help to cut that number dramatically.
“We are taking the test to the people rather than the other way around,” she said.
This point was backed by Benoit Battistelli, president of the European Patent Office, which is running the inventor awards.
“The test brings reliable diagnostics of HIV infection to areas where they are needed most and will also allow monitoring of the efficiency of medical treatments without laboratory infrastructure,” Battistelli said.
Apart from giving reliable diagnoses of HIV infection, Lee’s device can tell doctors the viral load — the amount of live virus material — that is flowing through a patient’s bloodstream. This a critical parameter for gauging drug dosages and was previously available only in advanced laboratory settings.
SAMBA works by drawing a blood sample from a patient and then feeding it into a disposable cartridge that contains chemicals, including a particular genetic sequence found only in HIV. These chemicals do not require refrigeration and amplify the viral DNA to generate a color change that appears on the cartridge. Two red lines on the side mean that person is positive for HIV. One line means they are uninfected. No line means that the test has not worked and needs to be retaken.
“So many devices for dealing with conditions like HIV are created in the developed world,” Lee said. “Then scientists try to adapt them to suit the developing world. That always causes problems. So we have designed our system to suit developing countries from the start.”
Chinese President Xi Jinping (習近平) is to visit Russia next month for a summit of the BRICS bloc of developing economies, Chinese Minister of Foreign Affairs Wang Yi (王毅) said on Thursday, a move that comes as Moscow and Beijing seek to counter the West’s global influence. Xi’s visit to Russia would be his second since the Kremlin sent troops into Ukraine in February 2022. China claims to take a neutral position in the conflict, but it has backed the Kremlin’s contentions that Russia’s action was provoked by the West, and it continues to supply key components needed by Moscow for
Japan scrambled fighter jets after Russian aircraft flew around the archipelago for the first time in five years, Tokyo said yesterday. From Thursday morning to afternoon, the Russian Tu-142 aircraft flew from the sea between Japan and South Korea toward the southern Okinawa region, the Japanese Ministry of Defense said in a statement. They then traveled north over the Pacific Ocean and finished their journey off the northern island of Hokkaido, it added. The planes did not enter Japanese airspace, but flew over an area subject to a territorial dispute between Japan and Russia, a ministry official said. “In response, we mobilized Air Self-Defense
CRITICISM: ‘One has to choose the lesser of two evils,’ Pope Francis said, as he criticized Trump’s anti-immigrant policies and Harris’ pro-choice position Pope Francis on Friday accused both former US president Donald Trump and US Vice President Kamala Harris of being “against life” as he returned to Rome from a 12-day tour of the Asia-Pacific region. The 87-year-old pontiff’s comments on the US presidential hopefuls came as he defied health concerns to connect with believers from the jungle of Papua New Guinea to the skyscrapers of Singapore. It was Francis’ longest trip in duration and distance since becoming head of the world’s nearly 1.4 billion Roman Catholics more than 11 years ago. Despite the marathon visit, he held a long and spirited
The pitch is a classic: A young celebrity with no climbing experience spends a year in hard training and scales Mount Everest, succeeding against some — if not all — odds. French YouTuber Ines Benazzouz, known as Inoxtag, brought the story to life with a two-hour-plus documentary about his year preparing for the ultimate challenge. The film, titled Kaizen, proved a smash hit on its release last weekend. Young fans queued around the block to get into a preview screening in Paris, with Inoxtag’s management on Monday saying the film had smashed the box office record for a special cinema